GLP-1 · GIP · Glucagon synergy
Triple Pathway
Retatrutide simultaneously activates GLP-1, GIP and glucagon receptors, delivering synergistic metabolic signalling and superior efficacy in models of weight management — laboratory research use only.
Triglycerides ↓ • Liver fat ↓
Cardio Gains
In clinical investigation retatrutide lowered fasting triglycerides and intra-hepatic fat by up to forty percent, supporting broader cardio-metabolic health markers. Strictly for research purposes only.
6-day half-life convenience
Weekly Dosing
Extended pharmacokinetics enable a straightforward once-weekly administration schedule, minimising handling time and improving study protocol adherence — for in-vitro or ex-vivo scientific research use only.